Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...

Shares of Soleno Therapeutics jumped 40% in morning trading on Thursday, after the company's drug for a rare metabolic condition became the first such treatment to receive U.S. regulatory nod.

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Shares of Soleno Therapeutics SLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR ...

ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $20.68. The firm has a market capitalization of $2.84 billion, a PE ratio of 21.83 and a beta of 0.43. Insiders Place ...

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of ACADIA ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

In this article, we are going to look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...